Excess mortality among opioid-using patients treated with oral naltrexone in Australia

Drug and Alcohol Review

Volumn 34, Issue 1, 2015, Pages 90-96

  Degenhardt, Louisa ^a,b,c,d   Larney, Sarah ^a,e   Kimber, Jo ^a,f   Farrell, Michael ^a   Hall, Wayne ^g,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BROWN UNIVERSITY   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Mortality; Naltrexone; Opioid dependence; Opioid substitution therapy; Treatment

Indexed keywords

METHADONE; NALTREXONE; NARCOTIC ANTAGONIST;

AUSTRALIA; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; MORTALITY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; ORAL DRUG ADMINISTRATION; PROCEDURES; UNITED STATES;

ADMINISTRATION, ORAL; AUSTRALIA; COHORT STUDIES; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NEW SOUTH WALES; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; WASHINGTON;

EID: 84921311040     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12205     Document Type: Article

References (41)

1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
2. Degenhardt L, Charlson F, Mathers B, etal. The global epidemiology and burden of disease attributable to opioid dependence: findings from the Global Burden of Disease Study 2010. Addiction 2014;109:1320-1333.
3. Degenhardt L, Whiteford H, Ferrari AJ, etal. The global burden of disease attributable to illicit drug use and dependence: results from the GBD 2010 study. Lancet 2013;382:1564-1574.
4. Darke S, Degenhardt L, Mattick RP, eds. Mortality amongst illicit drug users. Cambridge: Cambridge University Press, 2006.
5. Wang C, Vlahov D, Galai N, etal. The effect of HIV infection on overdose mortality. AIDS 2005;19:935-942.
6. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002;97:39-47.
7. O'Driscoll PT, McGough J, Hagan H, Thiede H, Critchlow C, Alexander ER. Predictors of accidental fatal drug overdose among a cohort of injection drug users. Am J Public Health 2001;91:984-987.
8. Degenhardt L, Hall W, Warner-Smith M. Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006;82(Suppl. 3):56-63.
9. Degenhardt L, Hall W, Lynskey M, Warner-Smith M. Illicit drug use, Chapter 13. In: Ezzati M, Lopez AD, Rodgers A, Murray R, eds. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, 2nd edn. Geneva: World Health Organization, 2004:1109-1176.
10. Kelty E, Hulse G. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction 2012;107:1817-1824.
11. World Health Organization. WHO model list of essential medicines, 14th edn. The headquarters of WHO are in Geneva. 2005. Available at: http://www.who.int/topics/essential_medicines/en/.
12. Ward J, Mattick RP, Hall W. Methadone maintenance treatment and other opioid replacement pharmacotherapies. Amsterdam: Harwood Academic Publishers, 1998.
13. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2003;(2):CD002209.
14. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011;(8):CD004145.
15. Degenhardt L, Bucello C, Mathers B, etal. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32-51.
16. Kimber J, Copeland L, Hickman M, etal. Survival and cessation in injecting opiate users, a prospective observational study of outcomes and the effect of opiate substitute treatment. BMJ 2010;340:c3172. doi: 10.1136/bmj.c3172.
17. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475.
18. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
19. National Health and Medical Research Council. Naltrexone implant treatment for opioid dependence: literature review. In: National Health and Medical Research Council, editor. Canberra, 2010. Available at: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ps0005_naltrexone_implant_treatment_literature_review.pdf (accessed June 2012).
20. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;(4):CD001333.
21. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse 2006;32:503-517.
22. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick R. Serious adverse events in the Australian national evaluation of pharmacotherapies for opioid dependence (NEPOD). Addiction 2004;99:450-460.
23. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007;26:405-410.
24. Gibson A, Degenhardt L, Hall W. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007;186:152-153.
25. Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev 2014;33:115-128.
26. Lobmaier P, Kornor H, Kunoe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD006140.
27. Hulse G, O'Neil G. Using naltrexone implants in the management of the pregnant heroin user. Aust N Z J Obstet Gynaecol 2002;42:569-573.
28. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Access to unapproved therapeutic goods via the Special Access Scheme. Woden: Therapeutic Goods Administration, 2009. Available at: http://www.tga.gov.au/pdf/access-sas-guidelines.pdf (accessed March 2013).
29. Australian Government Department of Health and Ageing. Special access scheme. In: Therapeutic Goods Administration, editor. Canberra: Australian Government Department of Health and Ageing, 2011. Available at: http://www.tga.gov.au/hp/access-sas.htm (accessed June 2012).
30. Hickman M, Degenhardt L, Farrell M, Hall W. Commentary on Kelty & Hulse (2012): is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison? Addiction 2012;107:1825-1826.
31. Fellows-Smith J. Opioid-dependent error processing. J Opioid Manag 2011;7:443-449.
32. Degenhardt L, Conroy E, Day C, Gilmour S, Hall W. The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug Alcohol Depend 2005;79:129-135.
33. Burns L, Randall D, Hall WD, etal. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009;104:1363-1372.
34. Bird S, Strang J, Hall W, Hickman M. How better methadone prescribing has saved more than 2, 500 lives. Straight Statistics. Mon, 27/09/2010, 2010. Available at: http://straightstatistics.org/article/how-better-methadone-prescribing-has-saved-more-2500-lives (accessed 18 September 2014).
35. Strang J, Hall W, Hickman M, Bird SM. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. BMJ 2010;341:c4851. doi: 10.1136/bmj.c4851.
36. Tucker TK, Ritter AJ, Maher C, Jackson H. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004;23:299-309.
37. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction 2000;95:687-695.
38. Ngo HT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation. Arch Gen Psychiatry 2008;65:457-465.
39. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction 2001;96:1113-1125.
40. NSW Department of Health. Opioid treatment program: clinical guidelines for methadone and buprenorphine treatment. In: Office MHaDaA, editor. Sydney, 2006. Available at: http://www0.health.nsw.gov.au/policies/gl/2006/pdf/GL2006_019.pdf (accessed May 2014).
41. Banscott Health Consulting Pty Ltd. Report of the review of access to unapproved therapeutic goods, 2005. Available at: http://www.tga.gov.au/pdf/archive/review-clinical-trials-050405.pdf (accessed August 2013).